BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Oncotelic Hopes to Leverage Intranasal Apomorphine to Treat Parkinson’s Disease

  Clinical trials have demonstrated that intermittent apomorphine injections provide rapid and effective relief from sudden, unexpected “off” periods brought on by primary Parkinson’s medicine, levodopa.

  October 4, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Amgen and Kyowa Kirin Notch Phase II Win in Atopic Dermatitis

  Four months after collaborating on an experimental atopic dermatitis treatment, Amgen and Kyowa Kirin are seeing the fruits of that deal with positive Phase II data.

  October 4, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  J&J Takes Lead in RSV Vaccine Race with 80% Efficacy in Phase II

  Data from the Phase II CYPRESS study presented at the virtual IDWeek (Infectious Disease Week) 2021 showed that the vaccine candidate provided a robust response against the infection.

  October 4, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Kymera’s Protein Degraders are Expanding the Druggable Universe

  The ability to utilize one protein degrader against a whole host of diseases drives Kymera’s strategy when choosing protein targets.

  October 4, 2021

   · 

  5 min read

   · 

  Maggie Chen
• 

  Drug Development

  Enanta Axes Two Farnesoid X Receptor Agonists for NASH

  Instead of continuing to develop the two different assets, EDP-305 and EDP-297, the company intends to seek an out-licensing deal to focus on infectious respiratory diseases.

  October 4, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  SPAC Market Remains Hot as MoonLake Therapeutics Hits the Nasdaq

  Once the deal is done, the company will be renamed MoonLake Immunotherapeutics and trade on the Nasdaq under the ticker symbol MLTX.

  October 4, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID-19 Update: J&J to Request Booster Authorization, Merck Antiviral Review a Priority

  Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for its one-shot COVID-19 vaccine this week.

  October 4, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca’s Enhertu on a Roll with Fourth Breakthrough Therapy Designation

  The FDA granted the latest designation based on the Phase III DESTINY-Breast03 trial on adult patients diagnosed with unresectable or metastatic HER2-positive breast cancer.

  October 4, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Xencor and Janssen Unite Again in Second Bispecific Antibodies Agreement

  The deal has a value of over one billion dollars, with highlights for Xencor including receiving a $100 million upfront payment, a $25 million equity investment, eligibility for plamotamab royalties and potential milestone payments worth up to $1.18 billion.

  October 4, 2021

   · 

  2 min read

   · 

  Ellen Camacho
• 

  Drug Development

  Biogen and Sage Present Positive Data for Breakthrough Depression Therapy

  Sage Therapeutics and Biogen announced positive results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder and postpartum depression.

  October 4, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN